Recombinant Human CCL27 Protein

Name: Recombinant Human CCL27 Protein
Brand: Beta LifeScience
SKU: BL-1790NP
Availability: InStock

BL-1790NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: Chemokines and receptors, Cytokines, Cytokines and growth factors, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human C-C Motif Chemokine 27 is produced by our E.coli expression system and the target gene encoding Phe25-Gly112 is expressed.
Accession	Q9Y4X3
Synonym	C-C Motif Chemokine 27; CC Chemokine ILC; Cutaneous T-Cell-Attracting Chemokine; CTACK; Eskine; IL-11 R-Alpha-Locus Chemokine; Skinkine; Small-Inducible Cytokine A27; CCL27; ILC; SCYA27
Gene Background	Human Chemokine (C-C Motif) Ligand 27 (CCL27) is a small cytokine that is a member of the CC chemokine family; it is expressed in numerous tissues, including gonads, thymus, placenta and skin. CCL27 elicits its chemotactic effects by binding to the chemokine receptor CCR10. Predominantly expressed in the skin, CCL27 is associated with T cell-mediated inflammation of the skin. Human and Mouse CCL27 share 84% sequence identity in the mature form.
Molecular Mass	10.1 KDa
Apmol Mass	6-12 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of 20mM PB, 100mM Nacl, 6% Trehalose, 4% Mannitol, 0.05% Tween80, pH7.0.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Chemotactic factor that attracts skin-associated memory T-lymphocytes. May play a role in mediating homing of lymphocytes to cutaneous sites. Binds to CCR10.
Subcellular Location	Secreted.
Protein Families	Intercrine beta (chemokine CC) family
Database References	HGNC: 10626 OMIM: 604833 KEGG: hsa:10850 STRING: 9606.ENSP00000259631 UniGene: Hs.648124
Tissue Specificity	Testis, thymus, placenta, ovary and skin.

Gene Functions References

Plasma CCL27 levels were significantly lower in the VCA-IgA-negative normal subjects than in either the VCA-IgA-positive healthy donorsor the NPC patients. PMID: 29295705
CCR10/CCL27 crosstalk mediated drug resistance, contributing to failure of proteasome-inhibitors in multiple myeloma. PMID: 27732933
detected in the nucleus in eczema, cytoplasm in psoriasis PMID: 27193975
CCL27 drives baseline recruitment of Herpes simplex virus-specific CD8 T cells expressing CCR10, while interferon-responsive CXCR3 ligands recruit additional cells in response to virus-driven inflammation. PMID: 28701399
We therefore concluded that the cross talk between TNFa and ROS after keratinocytes was exposed to radiation, triggered CCL27 secretion for subsequent inflammation response. PMID: 27879026
Our study showed that a higher immunostaining of CCL27 in supratumoral epidermis is associated with longer progression-free interval and melanoma-specific survival. PMID: 27325798
Our data supports previous reports showing IL-17 and -23 upregulation in association with Multiple sclerosis and potentially identify a previously unknown involvement for CCL27. PMID: 26295034
NOS2 and CCL27: clinical implications for psoriasis and eczema diagnosis and management. PMID: 25539641
Findings support the notion that CCR10 and its ligand CCL27 may contribute to the skin infiltration of malignant T-cells in mycosis fungoides and adult T-cell leukemia/lymphoma. PMID: 24970722
Our study suggests that CTACK/CCL27 may have a pivotal role in the early stage of psoriasis plaque formation, but should be downregulated in the later stage to induce inflammation characteristic for chronic psoriasis plaques PMID: 24710735
Seventeen mediators were identified in burn wound exudates (concentration range 0.0006-9 ng/mg total protein), including the skin-specific chemokine CCL27. PMID: 23980822
We show that the adult but not prenatal human keratinocytes produce and release large amounts of CCL27. PMID: 24037339
CCL27 chemokine implicates cholesteatoma keratinocytes as contributors in cholesteatoma progression. PMID: 23670528
low CCL27/CCR10 and CXCL12/CXCR4 intratumoral mRNA ratios are associated with melanoma progression PMID: 22526457
Serum concentrations of TARC and CTACK were significantly higher in AD (atopic dermatitis) children than in healthy controls, and correlated with severity of symptoms. PMID: 22017510
IL-1beta-induced CCL27 gene expression in normal human keratinocytes is regulated through the p38 MAPK/MSK1/Mnk1+2 as well as the IKKbeta/NF-kappaB signalling pathways. PMID: 21993219
expression of CCL27 and CCL17 in the inflammatory skin diseases: psoriasis, atopic dermatitis and acute allergic contact dermatitis induced in nickel-sensitive individuals PMID: 21707761
member of cytokine family; a chemokine PMID: 11821893
membrane of cytokine family PMID: 11821900
Serum CTACK levels in patients with atopic dermatitis(AD) and psoriasis vulgaris(pSv) were significantly higher. CTACK was strongly expressed in lesional ke-ratinocytes of patients with AD and PsV. PMID: 12642842
serum levels significantly correlated with disease activity in patients with atopic dermatitis PMID: 14767451
primary Th2-dominated inflammatory reaction in atopic dermatitis induced by TARC leads to an augmented skin-specific inflammatory reaction through CTACK. PMID: 15335355
PSGL-1 interacts with CCL27 (CTACK/ILC/ESkine), a skin-associated chemokine that attracts skin-homing T lymphocytes PMID: 15466853
CCL27 expression is under the control of NF-kappaB, and that NF-kappaB, as indicated by others, may be an attractive target for therapy in inflammatory skin diseases PMID: 15598438
IL-1alpha, TNF-alpha, CCL20, CCL27, and CXCL8 alarm signals are induced in human cells after allergen and irritant exposure PMID: 15679580
CCL28 produced by keratinocytes is mediated by different signal pathways from CCL27, and both CCL27 and CCL28 are involved in the pathogenesis of inflammatory skin diseases. PMID: 16433680
CCR10-CTACK/CCL27 interactions between circulating T cells and keratinocytes would seem to play an important role in the pathophysiology of mycosis fungoides. PMID: 16675558
LTB(4) may enhance TNF-alpha-induced CCL27 production by activating NF-kappaB via the BLT1/G(i/o)/PI3K/ERK pathway in human keratinocytes. PMID: 17581202
Human keratinocyte-derived skin tumors may evade T cell-mediated antitumor immune responses by down-regulating the expression of CCL27 through the activation of epidermal growth factor receptor (EGFR)-Ras-MAPK-signaling pathways. PMID: 18025475
Serum concentrations of CCL17, CCL22, and CCL27 correlate well with the extent and intensity of Atopic dermatitis (AD) in infants. Of the three Th2 chemokines examined, serum CCL27 correlated most significantly with the severity of AD PMID: 18266834
a novel mechanism for the recruitment of CCR10-positive T cells to skin-draining LN following the rapid release of preformed CCL27 from the epidermis PMID: 18453562
Significantly lower serum concentration of CXCL-9, CXCL-10, CCL-17, and IL-18 and higher concentration of CXCL-12 and CCL-27 were found in atopic dermatitis patients under 10 years old when compared to Control. PMID: 19639049

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.